Ѕ≥олог≥¤ > ÷исплатина

ѕов≥домл¤Їтьс¤ про те, що г≥перекспрес≥¤ супресорного гена nm 23 супроводжуЇтьс¤, ¤к правило, зб≥льшенн¤м чутливост≥ до д≥њ цисплатина. ƒан≥ результати отримано з досл≥джень in vitro на кл≥тинних л≥н≥¤х карциноми молочноњ залози людини MDA-MB-435, л≥н≥њ карциноми ¤Їчника OKAR-3 та л≥н≥њ меланоми  -1735-“ , а також при досл≥дженн≥ кл≥н≥чного матер≥алу пухлин молочноњ залози. ” вс≥х досл≥джуваних системах г≥перекспрес≥¤ nm 23 призвела до формуванн¤ у кл≥тинах великоњ к≥лькост≥ м≥жланцюгових зшивок ƒЌ  та зб≥льшенн¤ чутливост≥ до цисплатина [110].

÷≥кавими Ї дан≥ по переносу резисткнтного до цисплатина фенотипу при трансфекц≥њ ген≥в v-src. Ќепухлинн≥ еп≥тел≥альн≥ кл≥тини людини HAG-1 п≥сл¤ трансфекц≥њ гену v-src набували неопластичного фенотипу та резистентност≥ до цисплатина. ” трансформованих кл≥тинах спостер≥гали значне зменьшенн¤ формуванн¤ м≥жланцюгових зшивок ƒЌ  з њх посл≥довним швидким видаленн¤м. ѕ≥сл¤ обробки даних кл≥тин ≥нг≥б≥торами src-к≥наз знижувавс¤ р≥вень резистентност≥ до цисплатина. –езультати ц≥Їњ роботи вказують на можлив≥сть участ≥ продукту гена v-src в ≥ндукц≥њ резитентност≥ до цисплатина шл¤хом модул¤ц≥њ де¤ких шл¤х≥в репарац≥њ ƒЌ  [111].

јмпл≥ф≥кац≥¤ гена сорцина (кальц≥й-зв¤зуючого б≥лка з молекул¤рною масою 19-22кƒ) в де¤ких модельних системах асоц≥ювалас¤ з резистентним фенотипом [112]. ¬ажко зараз сказати, чи Ї резистентн≥сть пов`¤заною саме з сорцином чи разом з геном сорцина у кл≥тинах ампл≥ф≥кован≥ ≥ ≥нш≥, б≥льш важлив≥ дл¤ розвитку резистентност≥ гени.

“аким чином резистентн≥сть до цисплатина маЇ комплексний характер ≥ пов`¤зана з р¤дом особливостей кл≥тин на р≥вн≥ цитоплазматичноњ мемрани, внутр≥шньокл≥тинних систем детоксикац≥њ, систем репарац≥њ та порушенн¤ функц≥ональноњ активност≥ ген≥в p 53, bcl-2, fos, mdm 2, nm23та ≥нших.

—писок л≥тератури

„ехун ¬‘. –оль плазматичних мембран нормальних ≥ пухлинних кл≥тин в механ≥зм≥ реал≥зац≥њ цитотоксичних ефект≥в координац≥йних сполук платини [јвтореф дис ... докт мед наук].  иев: »Ёѕќ–, 1994. 40 сс.

2. Scanlon KJ, Kashani-Sabet M, Tone T, Funato T. Cisplatin resistance in human cancers. Pharmacol Ther 1991; 52:385-406.

3. Gately DP, S.B.Howell SB. Cellular accumulation of the anticancer agent cisplatin. Br J Cancer 1993; 67:1171-6.

4. Ohmori T, Morikage T. The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP). Jpn J Cancer Res 1993; 84: 83-92.

5. Scanlon KJ, Safistein RL, Thies H, Gross RB, Waxman S, Guttenplan JB. Inhibition of amino acid transport by cis-diamminedichloroplatinum (II) derivatives in L1210 murine leukemia cells. Cancer Res 1983; 43: 4211-5.

6. Andrews PA, Velury S, Mann SC, Howell SB. Cis-diamminedichloroplatinum II accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res 1988; 48: 68-73.

7. Richon VM, Schulte N, Eastman A. Multiple mechanisms of resistance to cis-diamminedichloroplatinum (II) in murine leukemia L1210 cells. Cancer Res 1987 47: 2056-61.

8. Zaman GJR, Lakelma J, Tellingen O, Beijnen J, Dekker H, Paulusma C, Oude Elferink RPJ, Baas F, Borst P. Role of glutathione in the export of compaunds from cells by the multidrug-resistance-associated protein. Proc Natl Acad Sci USA 1995; 92:7690-4.

9. Muller V, Meijer C, Zaman GJR. Overexpression of the gene encoding the multidrug resistance-assiciated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci USA 1994; 91: 13033-7.

10. Ishikawa T, Ali-Osman F. Glutathione-associated cis-diamminedichloroplatinum (II) metabolism and ATP-dependent efflux from leukemia cells. J Biol Chem 1993; 268: 20116-25.

11. Laurent G, Erickson LC, Sharkey NA, Kohn KW. DNA cross-linking and cytotoxicity induced by cis-diamminedichloroplatinum (II) in human normal and tumor cell lines. Cancer Res 1981; 41: 3347-51.

12. Sorenson CM, Barry MA, Eastman A. Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst 1990; 82: 749-55.

13. Olivero OA, Chang PK, Lopez-larraza DM, Semino-Mora MC, Poirier MC. Preferential formation and decreased removal of cisplatin-DNA adducts in chinese hamster ovary cell mitochondrial DNA as compared to nuclear DNA. Mutat Res 1997, 391(1-2): 79-86.

14. Giurgiovich AJ, Diwan BA, Olivero OA, Anderson LM, Rice JM, Poirier MC. Elevated mitochondrial cisplatin-DNA adduct levels in rat tissues after transplacental cisplatin exposure. Carcinogenesis 1997, 18(1): 93-6.

15. Gorczyca W, Gong I, Ardelt B, Traganos F, Darzynkiewicz Z. The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. Cancer Res 1993, 53(13): 3186-92.

16. el Alaoui S, Lawry J, Griffin M. The cell cycle and induction of apoptosis in a hamster fibrosarcoma cell line treated with anticancer drugs: its importance to solid tumor chemotherapy. J Neurooncol 1997, 31(1-2): 195-207.

17. Vaisman A, Varchenko M, Said I, Chaney SG. Cell cycle changes associated with formation of Pt-DNA adducts in human ovarian carcinoma cells with different cisplatin sensitivity. Cytometry 1997, 27(1): 54-64.

18. Nishio K, Saigo N. Effect of cisplatin on cell cycle regulators. Gan To Kagaku Ryoho 1994, 21(3): 289-94.

19. Dimanche-Boitrel MT, Micheau O, Hamman A, Haugg M, Eymin B, Chauffert B, Solary E. Contribution of the cyclin-dependent kinase inhibitor p27KIP1 to the confluence-dependent resistance of HT 29 human colon carcinoma cells. Int J Cancer 1998, 77(5): 796-802.

20. Gill JS, Mindebank AJ. Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. J Clin Invest 1998, 101(12): 2842-50.

21. Megyesi J, Safirstein RL, Price PM. Induction of p 21 WAF1?CIP1/SDI1 in kidney tubule cells affects the course of cisplatin-induced acute renal failure. J Clin Invest 1998, 101(4): 777-82.

22. Otto AM, Paddenberg R, Schubert S, Mannherz HG. Cell cycle arrest, micronucleus formation, and cell death in growth inhibition of MCF-7 breast cancer cells by tamoxifen and cisplatin. J Cancer Res Clin Oncol 1996, 122(10): 603-612.

23. Boersma AW, Nooter K, Oostrum RG, Stoter G. Quantification of apoptotic cells with fluorescein isothiocyanate-labeled annexin V in chinese hamster ovary cells cultures treated with cisplatin. Cytometry 1996, 24(2): 123-130.

24. Ormerod MG, O`Neill C, Robertson D, Helland LR, Harrap KR. Cis-diamminedichloroplatinum (II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 1996, 37(5): 463-471.

25. Uslu R, Jewett A, Bonavida B. Sensitization of human ovarian tumor cells by subtoxic CDDP to anti-fas antibody mediated cytotoxicity and apoptosis. Gynecol Oncol 1996, 62(2): 282-91.

26. Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM. The CD95(APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 1997, 57(17): 3823-9.

27. McGahon AJ, Costa Pereira AP, Daly L, Cotter TG. Chemotherapeutic drug-induced apoptosis in human leukaemic cells is independent of the Fas(APO-1/CD95) receptor/ligand system. Br J Haematol 1998, 101(3): 539-47.

28. Antoku K, Liu Z, Johnson DE. Inhibition of caspase proteases by CrmA enhances the resistance of human leukemia cells to multiple chemotherapeutic agents. Leukemia 1997, 11(10): 1665-72.

29. Chen Z, Naito M, Mashima T, Tsuruo T. Activation of actin-cleavable interleukin 1 beta-converting enzyme (ICE) family protease CPP-32 during chemotherapeutic agent-induced apoptosis in ovarian carcinoma cells. Cancer Res 1996, 56(22): 5224-9.

30. Marissen WE, Lloyd RE. Eukariotic translation initiation factor 4G is targeted for proteolytic cleavage by caspase 3 during inhibition of translation in apoptotic cells. Mol Cell Biol 1998, 18(12): 7565-74.

31. Kraker AJ, Moore CW. Accumulation of cis-diamminedichloroplatinum (II) and platinum analogues by platinum-resistant murine leukemia cells in vitro. Cancer Res 1988; 48: 9-13.

32. Eichholtz-Wirth H, Hietel B. The relationship between cisplatin sensitivity and drug uptake into mammalian cells in vitro. Br J Cancer 1986; 54: 239-43.

33. Kawai K, Kamatani N, Georges E, Ling V. Identification of a membrane glycoprotein overexpression in murine lymphoma sublines resistant to cis- diamminedichloroplatinum (II). J Biol Chem 1990; 265: 13137-42.

34. Ishikawa T, Wright CD, Ishizuka H. GS-X pump Is functionally overexpressed in cis-diamminedichloroplatinum (II)-resistant human leukemia HL-60 Cells and downregulated by cell differentiation. J Biol Chem 1994; 269: 29085-93.

35. Goto S, Yoshido K, MoriKawa T, Urata Y, Suzuki K,. Kondo T. Augmentation of transport for cisplatin-glutathione adduct in cisplatin-resistant cancer cells. Cancer Res 1995; 55: 4297-301.

36. Veneroni S, Zaffaroni N, Daidone MG, Benini E, Villa R, Silvestrini R. Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers. Eur J Cancer 1994; 30A: 1002-7.

37. Jedlitschky G, Leier J, Buchholz U, Barnouin K, Kurz G, Keppler D. Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res 1996; 56: 988-94.

1	2	3	4	5	6

Ќазва: ÷исплатина
ƒата публ≥кац≥њ: 2005-01-07 (2107 прочитано)